09.05.2023 - Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) - Catalyst Pharmaceuticals, Inc. ('Catalyst') (Nasdaq: ... Seite 1